Effect of radiation combined with p53 gene therapy and endostatin on mouse prostate cancer
10.3760/cma.j.issn.0254-5098.2009.03.003
- VernacularTitle:放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤
- Author:
Min ZHANG
;
Jun REN
;
Bo XU
;
Xianshu GAO
;
Zhisong HE
;
Xiaoming HE
;
Ming ZHANG
;
Chaoxing LIU
;
Xinyong HE
;
Guangming CAO
;
Shaolong ZHANG
- Publication Type:Journal Article
- Keywords:
Prostate cancer;
Genctberapy;
rAd p53;
Endostatin;
Radiation
- From:
Chinese Journal of Radiological Medicine and Protection
2009;29(3):259-264
- CountryChina
- Language:Chinese
-
Abstract:
Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.
